SPOTLIGHT: Symphogen pockets $25M

Danish biotech Symphogen has rounded up $25 million in its fourth round of venture capital, with Takeda Research Investment joining the investment group. Symphogen has a lead candidate now poised to enter the clinic and three other projects in earlier stages. Symphogen also has a few out-licensing deals in the works, telling BioWorld it expects to have two deals inked this year. Report